These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 1673757)

  • 1. Transient factor VIII inhibitor and treatment with monoclonal-antibody-purified factor VIII.
    Montoro JB; Rodríguez S; Altisent C; Tusell JM
    Lancet; 1991 May; 337(8751):1222. PubMed ID: 1673757
    [No Abstract]   [Full Text] [Related]  

  • 2. Transient inhibitor to monoclonal antibody-purified factor VIII concentrate.
    Votaw ML; Miller S
    Am J Hematol; 1992 Dec; 41(4):297. PubMed ID: 1288295
    [No Abstract]   [Full Text] [Related]  

  • 3. [Outcome of hemorrhage treatment in children with hemophilia A related to factor VIII inhibitor].
    Klukowska A; Zieleniewska B
    Acta Haematol Pol; 1994; 25(4):349-54. PubMed ID: 7847036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The development of the technology and capacity for the production of factor VIII for the treatment of hemophilia A.
    Aronson DL
    Transfusion; 1990 Oct; 30(8):748-58. PubMed ID: 2120808
    [No Abstract]   [Full Text] [Related]  

  • 5. [Inhibitor hemophilia A--diagnostic and therapeutic significance of controlled substitutions with factor VIII].
    Weippert M; Anders O; Schmidt M; Roewer J
    Beitr Infusionsther; 1990; 26():174-8. PubMed ID: 1703823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Viral safety and inhibitor development associated with monoclonal antibody-purified F VIII C.
    Lusher JM
    Ann Hematol; 1991 Sep; 63(3):138-41. PubMed ID: 1932288
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment of hemophilic patients with factor VIII inhibitor.
    Abildgaard CF; Britton M
    Ann N Y Acad Sci; 1975 Jan; 240():400-4. PubMed ID: 1053883
    [No Abstract]   [Full Text] [Related]  

  • 8. Factor VIII:C inhibitor associated with monoclonal-antibody-purified FVIII concentrate.
    Rodell MB; Bergman GE
    Lancet; 1990 Aug; 336(8711):373. PubMed ID: 1975350
    [No Abstract]   [Full Text] [Related]  

  • 9. Porcine factor VIII therapy in patients with factor VIII inhibitors.
    Hay C; Lozier JN
    Adv Exp Med Biol; 1995; 386():143-51. PubMed ID: 8851022
    [No Abstract]   [Full Text] [Related]  

  • 10. Lack of inhibitor to monoclonal-antibody purified factor VIII concentrate.
    Lusher JM
    Lancet; 1990 Nov; 336(8725):1249-50. PubMed ID: 1978087
    [No Abstract]   [Full Text] [Related]  

  • 11. Incidence of factor VIII inhibitor development in hemophilia A patients treated with less pure plasma derived concentrates.
    de Biasi R; Rocino A; Papa ML; Salerno E; Mastrullo L; De Blasi D
    Thromb Haemost; 1994 May; 71(5):544-7. PubMed ID: 8091377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factor VIII inhibitors.
    Gilles JG; Jacquemin MG; Saint-Remy JM
    Thromb Haemost; 1997 Jul; 78(1):641-6. PubMed ID: 9198231
    [No Abstract]   [Full Text] [Related]  

  • 13. Highly purified porcine factor VIII in haemophilia A.
    Hewitt P; Mackie IJ; Machin SJ
    Lancet; 1982 Mar; 1(8274):741-2. PubMed ID: 6122035
    [No Abstract]   [Full Text] [Related]  

  • 14. Comments on the development of inhibitor antibodies in patients using recombinant factor VIII concentrates.
    Brettler DB
    Semin Hematol; 1991 Apr; 28(2 Suppl 1):45-6. PubMed ID: 1908128
    [No Abstract]   [Full Text] [Related]  

  • 15. Development of circulating inhibitor directed against factor VIII in patients with haemophilia-A.
    Cohn J; Nielsen VG
    Scand J Haematol; 1972; 9(5):524-30. PubMed ID: 5074558
    [No Abstract]   [Full Text] [Related]  

  • 16. The optimal treatment for haemophiliacs who have developed factor VIII or -IX antibodies.
    Engelfriet CP; Reesink HW; Mannucci PM; Gringeri A; Ingerslev J; Brettler DB; Mauser-Bunschoten EP; Negrier C; Berntorp E; Smith OP; Shapiro AD
    Vox Sang; 2000; 78(4):256-61. PubMed ID: 10970234
    [No Abstract]   [Full Text] [Related]  

  • 17. Plasma exchange and human factor VIII concentrate in managing haemophilia A with factor VIII inhibitors.
    Wensley RT; Stevens RF; Burn AM; Delamore IW
    Br Med J; 1980 Nov; 281(6252):1388-9. PubMed ID: 6777018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factor VIII inhibitors in haemophilia.
    Lancet; 1983 Apr; 1(8327):742-3. PubMed ID: 6132087
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of low-dose 'factor VIII inhibitor bypassing activity (FEIBA)' in resistant haemophilia.
    Zwahlen H; Beck EA
    Acta Haematol; 1980; 64(1):12-7. PubMed ID: 6774572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factor VIII inhibitors.
    Hoyer LW
    Curr Opin Hematol; 1995 Sep; 2(5):365-71. PubMed ID: 9372021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.